RxDoctor Payments Data

Scott Yarmark, DO

Family Medicine · East Norriton, PANPI 1265548648

Payments from drug & device makers

$22,504in general payments, 2019–2025

Across 1,267 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • Pfizer$2K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • AstraZeneca$1K
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$430%
  • Food & beverage$22,15498%
  • Education$3071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk168$2,521
AbbVie(2 entities)131$2,164
Pfizer134$2,064
Lilly USA, LLC88$1,506
Amgen73$1,433
AstraZeneca67$1,428
GSK61$1,155
Astellas Pharma US Inc32$821
Sumitomo Pharma America, Inc.39$774
Bayer38$658
Sunovion Pharmaceuticals Inc.30$462
Novartis22$393
Merck24$360
Boehringer Ingelheim17$341
Otsuka America Pharmaceutical, Inc.16$319
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$304
Abbott15$293
Avanir Pharmaceuticals, Inc.14$278
Sanofi-aventis U.S. LLC16$266
Axsome Therapeutics, Inc.9$233
Teva Pharmaceuticals USA, Inc.14$229
Lundbeck LLC11$208
Amarin Pharma, Inc.14$206
Shield Therapeutics Inc6$194
Johnson & Johnson13$186
Daiichi Sankyo Inc.9$177
Exact Sciences7$159
Dexcom, Inc.7$153
Nestle Healthcare Nutrition Inc.8$149
Upsher-smith Laboratories LLC8$147
Sun Pharmaceutical Industries Inc.7$130
Phathom Pharmaceuticals, Inc.7$124
Supernus Pharmaceuticals, Inc.6$122
Paratek Pharmaceuticals, Inc.6$116
UCB, Inc.7$116
Neurocrine Biosciences, Inc.5$107
Biohaven Pharmaceuticals, Inc.5$107
Acadia Pharmaceuticals Inc7$104
Sanofi Pasteur Inc.5$100
Urovant Sciences Inc5$93
Intuity Medical Inc6$92
Biohaven Pharmaceutical Holding Company Ltd.5$88
Radius Health, Inc.6$85
Xeris Pharmaceuticals, Inc.4$82
Boston Scientific3$77
Verona Pharma, Inc.3$75
Ardelyx, Inc.3$75
Seqirus USA Inc3$68
E.r. Squibb & Sons, L.L.C.4$66
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$59
Eisai Inc.3$57
Takeda Pharmaceuticals U.S.A., Inc.3$55
Jazz Pharmaceuticals Inc.2$54
Regeneron Healthcare Solutions, Inc.3$53
Scilex Pharmaceuticals Inc.3$51
Biogen2$48
Shire North American Group Inc3$45
Zimmer Biomet1$45
Aimmune Therapeutics, Inc.2$44
Kowa Pharmaceuticals America, Inc.3$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,504 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$293,615
Medicare patients
741
Services billed
3,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban853$456,308
MounjaroTirzepatide148$195,836
TrulicityDulaglutide171$158,224
BiktarvyBictegrav/Emtricit/Tenofov Ala35$145,550
OzempicSemaglutide79$120,908
FarxigaDapagliflozin Propanediol152$116,125
JardianceEmpagliflozin141$111,985
Humira(Cf)Adalimumab12$80,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter119$79,977
XareltoRivaroxaban144$61,603
MyrbetriqMirabegron86$48,455
GemtesaVibegron125$33,556
JanuviaSitagliptin Phosphate45$30,017
LinzessLinaclotide44$26,542
Repatha SureclickEvolocumab20$26,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$2,064$464,426869 claims
Lilly USA, LLCMounjaro, Trulicity$1,506$354,059319 claims
GSKTrelegy Ellipta, Arexvy, Incruse Ellipta, Breo Ellipta$1,155$137,576282 claims
AstraZenecaFarxiga, Brilinta$1,428$129,846193 claims
Boehringer IngelheimJardiance, Tradjenta$341$128,097164 claims
AbbVieHumira(Cf), Linzess, Vraylar$2,164$125,43769 claims
Novo NordiskOzempic$2,521$120,90879 claims
Johnson & JohnsonXarelto$186$61,603144 claims
Astellas Pharma US IncMyrbetriq$821$48,45586 claims
MerckJanuvia, Belsomra$360$39,03960 claims
Sumitomo Pharma America, Inc.Gemtesa$774$33,556125 claims
NovartisEntresto$393$20,40340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in East Norriton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →